Trials / Completed
CompletedNCT00137397
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
A Multi-centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound. This will help doctors to understand whether there is a link between changes in the thickness of the bladder wall and progression of symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolterodine ER | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-11-01
- Completion
- 2006-08-01
- First posted
- 2005-08-29
- Last updated
- 2021-01-27
Locations
11 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00137397. Inclusion in this directory is not an endorsement.